Cindy K Blair1,2, David R Jacobs3, Wendy Demark-Wahnefried4,5, Harvey J Cohen6,7, Miriam C Morey6,7,8, Kim Robien9, DeAnn Lazovich3. 1. Department of Internal Medicine, University of New Mexico, Albuquerque, New Mexico. 2. Cancer Control and Population Sciences, University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico. 3. Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota. 4. Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, Alabama. 5. Cancer Prevention and Control, O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, Birmingham, Alabama. 6. Department of Medicine, Duke University Medical Center, Durham, North Carolina. 7. Claude D. Pepper Older Americans Independence Center/Center for the Study of Aging and Human Development, Duke University School of Medicine, Durham, North Carolina. 8. Geriatric Research, Education, and Clinical Care, VA Medical Center, Durham, North Carolina. 9. Department of Exercise and Nutrition Sciences, Milken Institute School of Public Health, The George Washington University, Washington, DC.
Abstract
BACKGROUND: Cancer, its treatment, and associated adverse effects may accelerate the functional aging of cancer survivors. In the current study, the authors used geriatric assessment (GA) to compare the functional age of long-term cancer survivors with that of similarly aged women without a cancer history, and to examine whether functional age influences all-cause mortality differently between these 2 groups. METHODS: Participants included 1723 cancer survivors and 11,145 age-matched, cancer-free women enrolled in the Iowa Women's Health Study in 1986 who completed the 2004 questionnaire (at ages 73-88 years). GA domain deficits included ≥2 physical function limitations, ≥2 comorbidities, poor general health, poor mental health, and underweight. The risk of all-cause mortality was estimated for deficits in each GA domain between 4 groups based on the cross-classification of the presence and/or absence of cancer history and GA domain deficit (the referent group was cancer-free women without a GA deficit). RESULTS: Both cancer history and GA domain deficits significantly predicted 10-year mortality for all GA domains. Cancer survivors without deficits had a 1.3-fold to 1.4-fold risk of mortality, similar to the 1.1-fold to 1.7-fold risk noted among cancer-free women with deficits (all P < .05). Cancer survivors with deficits were found to have the highest mortality risk for 4 of 5 domains (hazard ratio range, 1.6-2.0). Mortality risk increased with the increasing number of GA deficits, which was greater in cancer survivors compared with cancer-free women. CONCLUSIONS: Even without GA deficits, cancer survivors appear to have an excess risk of death compared with women without cancer, and these deficits add to mortality risk. Interventions are needed to maintain or improve functional/physiological capacity as women age, especially in cancer survivors.
BACKGROUND:Cancer, its treatment, and associated adverse effects may accelerate the functional aging of cancer survivors. In the current study, the authors used geriatric assessment (GA) to compare the functional age of long-term cancer survivors with that of similarly aged women without a cancer history, and to examine whether functional age influences all-cause mortality differently between these 2 groups. METHODS:Participants included 1723 cancer survivors and 11,145 age-matched, cancer-free women enrolled in the Iowa Women's Health Study in 1986 who completed the 2004 questionnaire (at ages 73-88 years). GA domain deficits included ≥2 physical function limitations, ≥2 comorbidities, poor general health, poor mental health, and underweight. The risk of all-cause mortality was estimated for deficits in each GA domain between 4 groups based on the cross-classification of the presence and/or absence of cancer history and GA domain deficit (the referent group was cancer-free women without a GA deficit). RESULTS: Both cancer history and GA domain deficits significantly predicted 10-year mortality for all GA domains. Cancer survivors without deficits had a 1.3-fold to 1.4-fold risk of mortality, similar to the 1.1-fold to 1.7-fold risk noted among cancer-free women with deficits (all P < .05). Cancer survivors with deficits were found to have the highest mortality risk for 4 of 5 domains (hazard ratio range, 1.6-2.0). Mortality risk increased with the increasing number of GA deficits, which was greater in cancer survivors compared with cancer-free women. CONCLUSIONS: Even without GA deficits, cancer survivors appear to have an excess risk of death compared with women without cancer, and these deficits add to mortality risk. Interventions are needed to maintain or improve functional/physiological capacity as womenage, especially in cancer survivors.
Authors: Sally S Ingram; Pearl H Seo; Robert E Martell; Elizabeth C Clipp; Martha E Doyle; Gustavo S Montana; Harvey J Cohen Journal: J Clin Oncol Date: 2002-02-01 Impact factor: 44.544
Authors: Catherine M Alfano; Juan Peng; Rebecca R Andridge; Monica E Lindgren; Stephen P Povoski; Adele M Lipari; Doreen M Agnese; William B Farrar; Lisa D Yee; William E Carson; Janice K Kiecolt-Glaser Journal: J Clin Oncol Date: 2016-11-28 Impact factor: 44.544
Authors: Kathryn E Weaver; Laura P Forsythe; Bryce B Reeve; Catherine M Alfano; Juan L Rodriguez; Susan A Sabatino; Nikki A Hawkins; Julia H Rowland Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-10-30 Impact factor: 4.254
Authors: Kirsten K Ness; Kevin R Krull; Kendra E Jones; Daniel A Mulrooney; Gregory T Armstrong; Daniel M Green; Wassim Chemaitilly; Webb A Smith; Carmen L Wilson; Charles A Sklar; Kyla Shelton; Deo Kumar Srivastava; Sabeen Ali; Leslie L Robison; Melissa M Hudson Journal: J Clin Oncol Date: 2013-11-18 Impact factor: 44.544
Authors: Ibrahim Y Abdelgawad; Karim T Sadak; Diana W Lone; Mohamed S Dabour; Laura J Niedernhofer; Beshay N Zordoky Journal: Pharmacol Ther Date: 2020-12-01 Impact factor: 12.310
Authors: Dori Pekmezi; Kevin Fontaine; Laura Q Rogers; Maria Pisu; Michelle Y Martin; Yu-Mei Schoenberger-Godwin; Robert A Oster; Kelly Kenzik; Nataliya V Ivankova; Wendy Demark-Wahnefried Journal: BMC Cancer Date: 2022-04-29 Impact factor: 4.638
Authors: Nataliya V Ivankova; Laura Q Rogers; Ivan I Herbey; Michelle Y Martin; Maria Pisu; Dorothy Pekmezi; Lieu Thompson; Yu-Mei M Schoenberger-Godwin; Robert A Oster; Kevin Fontaine; Jami L Anderson; Kelly Kenzik; David Farrell; Wendy Demark-Wahnefried Journal: JMIR Cancer Date: 2021-10-06